ABBV · 8-K · 20260903PR104940

Guidance / Outlook

AbbVie Inc. · 2026-09-03 · Importance 36 · Surprise 24 · In source text

AbbVie reaffirmed its 2026 full-year adjusted diluted EPS guidance range of $13.87 to $14.07. The full-year guidance includes a $0.14 per-share dilution from the completed Apogee acquisition and a $0.58 per-share unfavorable impact from acquired in-process research and development and milestones expense incurred through the second quarter. AbbVie also reaffirmed third-quarter 2026 adjusted diluted EPS guidance of $3.84 to $3.88. The third-quarter guidance excludes acquired IPR&D and milestone impacts incurred during the quarter because they cannot be reliably forecast.

Key facts

• The 2026 full-year adjusted diluted EPS guidance includes a $0.14 per share dilutive impact related to the completed Apogee acquisition. source
• AbbVie's 2026 adjusted diluted EPS guidance includes an unfavorable impact of $0.58 per share related to acquired IPR&D and milestones expense incurred year-to-date through the second quarter. source
• AbbVie's 2026 adjusted diluted EPS guidance excludes any impact from acquired IPR&D and milestones that may be incurred beyond the second quarter of 2026. source
• AbbVie's 2026 third-quarter adjusted diluted EPS guidance excludes any impact from acquired IPR&D and milestones that may be incurred in the quarter. source
• AbbVie reaffirmed its previously issued 2026 full-year adjusted diluted EPS guidance range of $13.87 - $14.07. source
• AbbVie reaffirmed its previously issued third-quarter 2026 adjusted diluted EPS guidance range of $3.84 - $3.88. source

Impact estimates